If the company really were pursuing making it's LSE listing tradable on the AIM growth market then there would need to be 3 things under process completed already:
1) Appointment of a "Nominated Advisor" (NOMAD). This would require a formal Regulatory News Service announcement stating something like: "Northwest Biotherapeutics has appointed XXXX as its Nominated Advisor and Broker."
There is no evidence of this having happened to date.
2) Publication of an Admission Document or Prospectus. A massive legal filing is necessary in order to become tradable. As a publicly listed company this prospectus would need to be published on the Investor section of the NWBO website.
There is no evidence of this so far.
3) Announcement of the creation of Depository Interests (DIs). As NWBO is a Delaware company, UK investors can't hold the shares directly; they hold DIs that represent the shares. This allows for the shares to be settleable electronically in the UK under the CREST system.
At the moment the 0K95 ticker remains on the "International Reporting Service," which does not support standard retail CREST settlement or infer that DIs have been created.
Therefore - at least at the moment - there is no public evidence that a formal re-listing of 0K95 is underway to make it eligible for trading LSE. It has been suggested that trading is supposed to begin imminently on the 19th January, however if this were the case, I believe that there would surely be some of the evidence above in the public domain already. There is not...
Market Data 
Markets 
AI
